Sprint Bioscience AB Statistics
Want to see SE:SPRINT full AI Analyst Report?
Sprint Bioscience AB (SPRINT) Stock Statistics & Valuation Metrics
Total Valuation
Sprint Bioscience AB has a market cap or net worth of SEK 396.74M. The enterprise value is SEK 343.57M.
- Market Cap
- SEK 396.74M
- Enterprise Value
- SEK 343.57M
Share Statistics
Sprint Bioscience AB has 105,515,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 105,515,540
- Owned by Insiders
- ―
- Owned by Institutions
- 0.20%
Financial Efficiency
Sprint Bioscience AB’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is 81.67%.
- Return on Equity (ROE)
- 0.77
- Return on Assets (ROA)
- 0.67
- Return on Invested Capital (ROIC)
- 81.67%
- Return on Capital Employed (ROCE)
- 0.82
- Revenue Per Employee
- 5.22M
- Profits Per Employee
- 2.87M
- Employee Count
- 32
- Asset Turnover
- 1.22
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Sprint Bioscience AB is 5.22. Sprint Bioscience AB’s PEG ratio is 0.02.
- PE Ratio
- 5.22
- PS Ratio
- 2.85
- PB Ratio
- 4.40
- Price to FCF
- 5.80
- Price to Operating Cash Flow
- 5.75
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Sprint Bioscience AB had revenue of 167.17M and earned 91.74M in profits. Earnings per share was 0.99.
- Revenue
- 167.17M
- Gross Profit
- 97.33M
- Operating Income
- 97.33M
- Pretax Income
- 91.74M
- Net Income
- 91.74M
- EBITDA
- 98.40M
- Earnings Per Share (EPS)
- 0.99
Cash Flow
In the last 12 months, operating cash flow was 68.95M and capital expenditures -504,000, giving a free cash flow of 68.45M billion.
- Operating Cash Flow
- 68.95M
- Free Cash Flow
- 68.45M
- Free Cash Flow per Share
- 0.65
Dividends & Yields
Sprint Bioscience AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 16.68%
- Earnings Yield
- 18.43%
Stock Price Statistics
- Beta
- 1.49
- 52-Week Price Change
- 461.19%
- 50-Day Moving Average
- 3.31
- 200-Day Moving Average
- 3.16
- Relative Strength Index (RSI)
- 56.63
- Average Volume (3m)
- 283.59K
Important Dates
Sprint Bioscience AB upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 11, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Sprint Bioscience AB as a current ratio of 7.60, with Debt / Equity ratio of 0.00%
- Current Ratio
- 7.60
- Quick Ratio
- 7.60
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.29
- Interest Coverage Ratio
- 15.68
Taxes
In the past 12 months, Sprint Bioscience AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Sprint Bioscience AB EV to EBITDA ratio is 4.00, with an EV/FCF ratio of 4.63.
- EV to Sales
- 2.28
- EV to EBITDA
- 4.00
- EV to Free Cash Flow
- 4.63
- EV to Operating Cash Flow
- 4.60
Balance Sheet
Sprint Bioscience AB has SEK 93.26M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 93.26M billion.
- Cash & Marketable Securities
- SEK 93.26M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 93.26M
- Net Cash Per Share
- SEK 0.88
- Tangible Book Value Per Share
- SEK 0.85
Margins
Gross margin is 78.03%, with operating margin of 56.21%, and net profit margin of 54.37%.
- Gross Margin
- 78.03%
- Operating Margin
- 56.21%
- Pretax Margin
- 54.37%
- Net Profit Margin
- 54.37%
- EBITDA Margin
- 56.99%
- EBIT Margin
- 56.21%
Analyst Forecast
The average price target for Sprint Bioscience AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 135.48%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 79
